Evidence map›Paper›PMID 42542632›Full record

ArticleEClinicalMedicine2026

Safety and feasibility of oral zinc for patients with

Moritz Thiel, Kyriakos Martakis, Ibrahim Duran, Hormos S Dafsari, Petra Schiller, Jithmi Weliwitage, Barbara Hero, Yonika Larasati, Alexey Koval, Vladimir L Katanaev and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Moritz ThielDepartment of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Kyriakos MartakisDepartment of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Ibrahim DuranDepartment of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Hormos S DafsariDepartment of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Petra SchillerInstitute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Jithmi WeliwitageInstitute of Medical Statistics and Computational Biology (IMSB), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Barbara HeroDepartment of Paediatric Oncology and Hematology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.
Yonika LarasatiTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Alexey KovalTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Vladimir L KatanaevTranslational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Anne KoyDepartment of Paediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: ZINCGNAO1 was a 6-month, open-label, fixed-dose, single-centre pilot trial in Germany. Eligible participants were aged 6 months to 30 years, had a genetically confirmed Findings: Between Aug 2, 2024, and Jan 27, 2025, 13 participants with 11 different genetic variants were enrolled; 11 completed the follow up of the trial. Mean age at inclusion was 8.0 years (range 0.5-25.1). Overall treatment feasibility was 84.6% (11/13). No treatment-related serious adverse events occurred, and laboratory monitoring did not identify clinically relevant safety concerns during the 6-month treatment period. Exploratory secondary outcomes showed no change in MD severity. The mean BFMDRS Disability Score decreased from 25.5 (SD 2.6) to 23.5 (SD 2.8; nominal p = 0.005). Mean GMFM-66 increased from 33.1 (SD 12.8) to 37.8 (SD 12.8, nominal p = 0.006). COPM-P increased from 2.6 (SD 0.8) to 3.8 (SD 1.3; nominal p = 0.003), and COPM-S from 2.7 (SD 0.9) to 4.1 (SD 1.7; nominal p = 0.002). CPCHILD and seizure occurrence showed no clear treatment-related change; two participants had seizures during the trial. Interpretation: Our preliminary findings show that oral zinc supplementation was safe and feasible in this Funding:

Indexed as

Developmental and epileptic encephalopathyGNAO1-related disorderPaediatric movement disordersPrecision medicineSafety and feasibilityZinc acetate

Identifiers

PMID42542632
PMCPMC13427569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.